Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced financial and operating results for the first quarter ended March 31, 2013 and other business updates.

Total product revenue was $202.6 million for the first quarter of 2013, an 18% increase compared to $171.1 million for the first quarter of 2012. XIFAXAN® revenue for the first quarter of 2013 was $153.3 million, a 36% increase compared to $112.9 million for the first quarter of 2012.